🇺🇸 UTHR — United Therapeutics Corporation
Salud CompraPrecio actual
608,49 USD
Máx. histórico
608,49
0 días
Split 2:1 del 23/09/2009
Caída desde máximo
En máximo
Rango 52 semanas
432,53 – 614,23
Variación hoy
+1,19%
Cierre anterior
601,32
Rango de hoy
578,28 – 614,23
Volumen hoy
908.530
Peor caída histórica
-93,18%
12/07/2000 → 10/12/2001
Recuperado en 3311 días
Volatilidad anualizada ⓘ
46,95%
- Nombre completo
- United Therapeutics Corporation
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Drug Manufacturers - Specialty & Generic
- Empleados
- 1.400
- PER ⓘ
- 21,57 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 670,93 USD (puede no estar actualizado)
- Primera cotización
- 17/06/1999
- Precio actualizado
- hace 3 horas
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
| Fecha | Ratio |
|---|---|
| 23/09/2009 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 04/04/2023 | 223,58 | 227,42 | 222,46 | 227,18 | +0,83% | 2,22% | 433.800 |
| 03/04/2023 | 223,84 | 227,05 | 223,08 | 225,32 | +0,61% | 1,77% | 473.200 |
| 31/03/2023 | 220,06 | 224,24 | 218,22 | 223,96 | +2,26% | 2,74% | 671.700 |
| 30/03/2023 | 217,23 | 219,27 | 214,02 | 219,00 | +0,81% | 2,42% | 518.400 |
| 29/03/2023 | 218,79 | 219,22 | 215,89 | 217,23 | -0,77% | 1,52% | 378.600 |
| 28/03/2023 | 218,48 | 221,85 | 218,15 | 218,92 | +0,42% | 1,69% | 442.900 |
| 27/03/2023 | 220,15 | 221,96 | 214,62 | 218,01 | -0,88% | 3,33% | 492.100 |
| 24/03/2023 | 216,02 | 220,39 | 213,03 | 219,94 | +1,81% | 3,41% | 490.700 |
| 23/03/2023 | 213,34 | 216,35 | 212,15 | 216,02 | +1,42% | 1,97% | 862.900 |
| 22/03/2023 | 221,54 | 222,98 | 212,67 | 212,99 | -4,20% | 4,65% | 569.000 |
| 21/03/2023 | 226,86 | 228,48 | 220,57 | 222,33 | -1,23% | 3,49% | 584.100 |
| 20/03/2023 | 220,88 | 225,63 | 218,82 | 225,11 | +2,45% | 3,08% | 443.500 |
| 17/03/2023 | 221,20 | 221,20 | 216,18 | 219,73 | -0,15% | 2,27% | 1.246.400 |
| 16/03/2023 | 215,64 | 220,21 | 211,58 | 220,05 | +1,17% | 4,00% | 643.000 |
| 15/03/2023 | 219,00 | 221,39 | 216,05 | 217,50 | -1,43% | 2,44% | 503.200 |
| 14/03/2023 | 225,06 | 226,50 | 218,92 | 220,66 | -1,81% | 3,37% | 916.200 |
| 13/03/2023 | 227,45 | 233,07 | 223,91 | 224,72 | -1,77% | 4,03% | 646.800 |
| 10/03/2023 | 225,74 | 230,97 | 225,22 | 228,77 | +1,56% | 2,55% | 758.900 |
| 09/03/2023 | 222,88 | 225,46 | 218,52 | 225,26 | +1,18% | 3,11% | 1.187.000 |
| 08/03/2023 | 235,99 | 236,41 | 221,27 | 222,64 | -5,97% | 6,42% | 1.605.900 |
| 07/03/2023 | 248,03 | 248,03 | 236,53 | 236,77 | -4,54% | 4,64% | 640.500 |
| 06/03/2023 | 247,60 | 249,02 | 245,38 | 248,02 | -0,27% | 1,47% | 372.000 |
| 03/03/2023 | 245,00 | 249,22 | 243,16 | 248,69 | +1,61% | 2,47% | 289.000 |
| 02/03/2023 | 245,05 | 246,43 | 240,97 | 244,76 | -0,05% | 2,23% | 362.400 |
| 01/03/2023 | 245,10 | 248,70 | 241,21 | 244,89 | -0,47% | 3,06% | 575.100 |
| 28/02/2023 | 247,06 | 250,63 | 243,03 | 246,04 | -0,36% | 3,08% | 2.995.800 |
| 27/02/2023 | 249,45 | 252,25 | 246,50 | 246,93 | -1,13% | 2,31% | 505.400 |
| 24/02/2023 | 248,48 | 251,09 | 247,70 | 249,76 | +0,56% | 1,36% | 580.200 |
| 23/02/2023 | 243,75 | 254,58 | 243,75 | 248,36 | +1,89% | 4,44% | 718.100 |
| 22/02/2023 | 239,56 | 256,05 | 238,90 | 243,75 | -4,51% | 7,16% | 972.400 |